 The case centered around the FDA's sweeping deregulation of mifepristone in 2016 and 2021, allowing near unfettered access to the drug. The FDA's deregulation changes allows the drug to be used through the 10th week of pregnancy rather than only through the 7th week, allows health care providers, which are not physicians, to prescribe the drugs, and the drug can be prescribed through telehealth appointments and sent through the mail.